Archemix, a Cambridge, MA-based biotech developing aptamer drugs for the treatment of chronic and acute diseases, has sold its assets in the hemophilia space to Baxter International, according to an announcement today. Baxter (NYSE: [[ticker:BAX]]) will pay Archemix $30 million upfront and up to $285 million in milestone payments in an exclusive license agreement for the assets, which include ARC19499, a hemophilia treatment in a Phase 1 clinical trial in the U.K. The deal is expected to close this year.
Author: Erin Kutz
Erin Kutz has a background in covering business, politics and general news. She holds a bachelor’s degree in journalism from Boston University. Erin previously worked in the Boston bureau of Reuters, where she wrote articles on the investment management and mutual fund industries. While in college, she researched for USA Today reporter Jayne O’Donnell’s book, Gen Buy: How Tweens, Teens and Twenty-Somethings Are Revolutionizing Retail. She also spent a semester in Washington, DC, reporting Capitol Hill stories as a correspondent for two Connecticut newspapers and interning in the Money section of USA Today, where she assisted with coverage on the retail and small business beats. Erin got her first taste of reporting at Boston University’s independent student newspaper, as a city section reporter and fact checker and editor of the paper’s weekly business section.
View all posts by Erin Kutz
